ATE291898T1 - Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason - Google Patents

Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason

Info

Publication number
ATE291898T1
ATE291898T1 AT00985666T AT00985666T ATE291898T1 AT E291898 T1 ATE291898 T1 AT E291898T1 AT 00985666 T AT00985666 T AT 00985666T AT 00985666 T AT00985666 T AT 00985666T AT E291898 T1 ATE291898 T1 AT E291898T1
Authority
AT
Austria
Prior art keywords
fluticasone
aerosol formulation
pharmaceutical aerosol
formulation containing
salmeterol
Prior art date
Application number
AT00985666T
Other languages
English (en)
Inventor
Alan Leslie Cripps
Paul Johnson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930878.5A external-priority patent/GB9930878D0/en
Priority claimed from GB0018686A external-priority patent/GB0018686D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE291898T1 publication Critical patent/ATE291898T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00985666T 1999-12-24 2000-12-21 Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason ATE291898T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930878.5A GB9930878D0 (en) 1999-12-24 1999-12-24 Pharmaceutical formulation
GB0018686A GB0018686D0 (en) 2000-07-28 2000-07-28 Pharmaceutical formulation
PCT/GB2000/004939 WO2001047493A1 (en) 1999-12-24 2000-12-21 Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate

Publications (1)

Publication Number Publication Date
ATE291898T1 true ATE291898T1 (de) 2005-04-15

Family

ID=26244762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00985666T ATE291898T1 (de) 1999-12-24 2000-12-21 Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason

Country Status (8)

Country Link
US (1) US20030032632A1 (de)
EP (1) EP1248597B1 (de)
JP (1) JP2003518484A (de)
AT (1) ATE291898T1 (de)
AU (1) AU2206801A (de)
DE (1) DE60019167T2 (de)
ES (1) ES2238334T3 (de)
WO (1) WO2001047493A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
JP2003514841A (ja) * 1999-11-23 2003-04-22 グラクソ グループ リミテッド サルメテロールの医薬製剤
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU5070100A (en) 2000-05-22 2001-12-03 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
GB2367011A (en) * 2000-08-26 2002-03-27 Glaxo Group Ltd Metered dose inhaler for salmeterol
PE20020387A1 (es) * 2000-08-31 2002-06-24 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
EP1415647A1 (de) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Langwirkende beta-2-Agonisten in ultrafeiner Formulierung
ATE384001T1 (de) * 2002-08-27 2008-02-15 Schering Corp Verfahren zur herstellung von dosierinhalatorformulierungen
EP1595531A1 (de) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stabile Arzneimittellösung für Druckdosierinhalatoren
AU2005293328B2 (en) * 2004-10-12 2010-09-30 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US7680778B2 (en) * 2007-01-19 2010-03-16 Microsoft Corporation Support for reverse and stemmed hit-highlighting
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
US20130064870A1 (en) * 2010-05-20 2013-03-14 Sun Pharma Advanced Research Company Limited Dry powder inhalation composition
TWI399202B (zh) * 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
BR112014003907A2 (pt) 2011-08-19 2017-06-13 Intech Biopharm Ltd. método para preparar inalador pulverizado de dose medida para tratar doença respiratória
CN102379846B (zh) * 2011-10-21 2014-07-02 江苏长风药业有限公司 以氢氟烷烃和聚乙二醇为辅料氟替卡松丙酸酯气雾剂制剂
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PT3517541T (pt) 2012-05-08 2020-08-28 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
EP4233950B1 (de) * 2014-06-25 2025-06-25 Optinose, Inc. Nasale verabreichung
US20170189329A1 (en) 2014-07-29 2017-07-06 3M Innovative Properties Company Method of preparing a pharmaceutical composition
US10888546B2 (en) 2016-09-19 2021-01-12 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
ES2877575T3 (es) 2016-09-19 2021-11-17 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende salmeterol
ES2949975T3 (es) 2016-09-19 2023-10-04 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende indacaterol
US20240238309A1 (en) * 2020-03-25 2024-07-18 Insmed Incorporated Pharmaceutical formulations of treprostinil prodrugs and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629985A (de) * 1962-11-29
CH634480A5 (de) * 1977-11-25 1983-02-15 Schwarzkopf Gmbh Hans Unter druck stehendes aerosolpraeparat.
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
JP2769925B2 (ja) * 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
WO1994013262A1 (en) * 1992-12-09 1994-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
ES2244008T3 (es) * 1996-12-04 2005-12-01 Link Products Limited Composiciones farmaceuticas y dispositivos para su administracion.
JP2001511160A (ja) * 1997-02-05 2001-08-07 ヤゴ リサーチ アクチェンゲゼルシャフト 医学用エアゾール配合物
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
JP2003522102A (ja) * 1998-06-18 2003-07-22 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ２種以上の活性物質を含むエアゾール用医薬製剤
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6231519B1 (en) * 1999-05-04 2001-05-15 Nokia Corporation Method and apparatus for providing air quality analysis based on human reactions and clustering methods
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
FR2798290B1 (fr) * 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
PL357555A1 (en) * 2000-01-31 2004-07-26 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes

Also Published As

Publication number Publication date
WO2001047493A1 (en) 2001-07-05
AU2206801A (en) 2001-07-09
DE60019167T2 (de) 2006-05-11
EP1248597A1 (de) 2002-10-16
ES2238334T3 (es) 2005-09-01
DE60019167D1 (de) 2005-05-04
JP2003518484A (ja) 2003-06-10
US20030032632A1 (en) 2003-02-13
EP1248597B1 (de) 2005-03-30

Similar Documents

Publication Publication Date Title
DE60019167D1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
DE60031504D1 (de) Fluticasonpropionat arzneizubereitung
DE60308997D1 (de) Formulierungen zur inhalation
PT1037604E (pt) Composicoes farmaceuticas de aerossol
ID29181A (id) Kombinasi formoterol dan garam tiotropium
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
PT1123120E (pt) Formulacao medicinal em aerossol
NZ298169A (en) Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
ID30171A (id) Kombinasi formoterol dan mometason furoat untuk asma
EP1135173A4 (de) Medikamenthaltige zusammensetzung in aerosolform
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
MXPA03001752A (es) Uso de la combinacion de salmeterol y propionato de fluticasona.
WO2002000191A3 (de) Bdellosomen
DE60017450D1 (de) Pharmazeutische formulierungen enthaltend salmeterol
WO2002007672A3 (en) A medicinal aerosol formulation
CA2446562A1 (en) Pharmaceutical formulation of fluticasone propionate
AU2003300230A1 (en) Dosing aerosols containing lecithin as a surface-active substance

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties